George J Joseph

679 total citations
25 papers, 537 citations indexed

About

George J Joseph is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, George J Joseph has authored 25 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 10 papers in Hematology and 9 papers in Genetics. Recurrent topics in George J Joseph's work include Rheumatoid Arthritis Research and Therapies (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). George J Joseph is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). George J Joseph collaborates with scholars based in United States, India and Switzerland. George J Joseph's co-authors include Mark W. Smith, David J. Harrison, Annie Guérin, Vernon F. Schabert, Dominick Latrémouille-Viau, Jeffrey R. Curtis, David H. Collier, Patrick Gagnon‐Sanschagrin, Richard L. Kravitz and Steven M. Asch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

George J Joseph

25 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George J Joseph United States	15	176	147	109	104	92	25	537
Bradley S. Stolshek United States	16	139 0.8×	120 0.8×	142 1.3×	84 0.8×	29 0.3×	44	753
Namita Tundia United States	14	231 1.3×	106 0.7×	69 0.6×	36 0.3×	48 0.5×	40	621
Alessandra Maciel Almeida Brazil	15	249 1.4×	131 0.9×	188 1.7×	139 1.3×	20 0.2×	67	700
Caitlyn T. Wilke United States	8	161 0.9×	69 0.5×	70 0.6×	189 1.8×	18 0.2×	9	624
Florina Constantinescu United States	12	200 1.1×	68 0.5×	80 0.7×	34 0.3×	26 0.3×	22	494
Diana Sun United States	11	43 0.2×	68 0.5×	161 1.5×	65 0.6×	36 0.4×	34	600
Gianluca Furneri Italy	12	99 0.6×	43 0.3×	54 0.5×	108 1.0×	14 0.2×	50	563
Adewale Adebajo United Kingdom	12	444 2.5×	228 1.6×	359 3.3×	25 0.2×	31 0.3×	41	734
Keng Thye Woo Singapore	15	86 0.5×	102 0.7×	79 0.7×	16 0.2×	62 0.7×	81	777
Vandana Ahluwalia Canada	13	441 2.5×	183 1.2×	93 0.9×	30 0.3×	90 1.0×	35	639

Countries citing papers authored by George J Joseph

Since Specialization

Citations

This map shows the geographic impact of George J Joseph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George J Joseph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George J Joseph more than expected).

Fields of papers citing papers by George J Joseph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George J Joseph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George J Joseph. The network helps show where George J Joseph may publish in the future.

Co-authorship network of co-authors of George J Joseph

This figure shows the co-authorship network connecting the top 25 collaborators of George J Joseph. A scholar is included among the top collaborators of George J Joseph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George J Joseph. George J Joseph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Volk, Michael L., et al.. (2021). Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States. Journal of Medical Economics. 24(1). 202–211. 20 indexed citations

Joseph, George J, Dominick Latrémouille-Viau, Patrick Gagnon‐Sanschagrin, et al.. (2019). Vaso-Occlusive Crises and Costs of Sickle Cell Disease from a Commercial Payer's Perspective. Blood. 134(Supplement_1). 3464–3464. 2 indexed citations

Stein, Eytan M., Dominick Latrémouille-Viau, George J Joseph, et al.. (2019). Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis. Blood. 134(Supplement_1). 3495–3495. 7 indexed citations

Ritchie, Ellen K., Dominick Latrémouille-Viau, Annie Guérin, et al.. (2019). Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. Leukemia & lymphoma. 60(6). 1476–1484. 5 indexed citations

Seiter, Karen, Dominick Latrémouille-Viau, Annie Guérin, et al.. (2018). Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Advances in Therapy. 35(10). 1671–1685. 12 indexed citations

Stein, Eytan M., Gaetano Bonifacio, Dominick Latrémouille-Viau, et al.. (2018). Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. Journal of Medical Economics. 21(6). 556–563. 31 indexed citations

Stein, Eytan M., Min Yang, Annie Guérin, et al.. (2018). Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. Health and Quality of Life Outcomes. 16(1). 193–193. 18 indexed citations

Ritchie, Ellen K., Dominick Latrémouille-Viau, Annie Guérin, et al.. (2017). Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation. Blood. 130. 3396–3396. 1 indexed citations

Latrémouille-Viau, Dominick, et al.. (2017). Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Journal of Managed Care & Specialty Pharmacy. 23(2). 214–224. 30 indexed citations

10.

Ritchie, Ellen K., Johannes Wolff, Dominick Latrémouille-Viau, et al.. (2017). Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.. Journal of Clinical Oncology. 35(15_suppl). 7052–7052. 3 indexed citations

11.

Cannon, Grant W., Scott L. DuVall, Liron Caplan, et al.. (2016). Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Advances in Therapy. 33(8). 1347–1359. 18 indexed citations

12.

Gibofsky, Allan, et al.. (2015). Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).. PubMed. 33(3). 297–301. 3 indexed citations

13.

Curtis, Jeffrey R., Benjamin Chastek, Laura Becker, et al.. (2015). Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population. Journal of Managed Care & Specialty Pharmacy. 21(4). 318–328. 31 indexed citations

14.

Cannon, Grant W., Scott L. DuVall, Liron Caplan, et al.. (2014). Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. The Journal of Rheumatology. 41(10). 1935–1943. 25 indexed citations

15.

Curtis, Jeffrey R., Vernon F. Schabert, Jason Yeaw, et al.. (2014). Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. Journal of Medical Economics. 17(8). 555–566. 20 indexed citations

16.

Curtis, Jeffrey R., Vernon F. Schabert, David J. Harrison, et al.. (2014). Estimating Effectiveness and Cost of Biologics for Rheumatoid Arthritis: Application of a Validated Algorithm to Commercial Insurance Claims. Clinical Therapeutics. 36(7). 996–1004. 25 indexed citations

17.

Bonafede, Machaon, George J Joseph, Nicole Princic, & David J. Harrison. (2013). Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. Journal of Medical Economics. 16(9). 1120–1128. 20 indexed citations

18.

Schabert, Vernon F., et al.. (2013). Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population. Journal of Managed Care Pharmacy. 19(8). 621–630. 56 indexed citations

19.

Shrank, William H., Steven M. Asch, George J Joseph, et al.. (2006). Physicians’ Perceived Knowledge of and Responsibility for Managing Patients’ Out-of-Pocket Costs for Prescription Drugs. Annals of Pharmacotherapy. 40(9). 1534–1540. 35 indexed citations

20.

Shrank, William H., George J Joseph, Niteesh K. Choudhry, et al.. (2006). Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?. PubMed. 12(9). 545–51. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact